On May 23, 2023 Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, reported that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline (Press release, Pathos AI, MAY 23, 2023, View Source [SID1234631984]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
FT-7051 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in phase I development. FT-7051 (renamed P-300) was evaluated in prostate cancer and has potential for development in multiple tumor types. The molecule inhibits the CBP/p300 protein, which is involved in the activation of genes that promote cancer cell growth and proliferation.
The development of this molecule reflects Pathos’ commitment to precision medicine and biomarker-driven approaches in cancer treatment. "P-300 has shown promising phase I data and we are confident that leveraging our PathOS PlatformTM will enhance an optimized path toward a broader patient population that could benefit from this therapeutic option." explained Ryan Fukushima, Pathos CEO. "We are thrilled about this licensing agreement with Novo Nordisk and accelerating the development for this CBP/p300 inhibitor program."
The license will enable Pathos to continue the development of the drug and bring it to market as quickly and as safely as possible. Pathos has not yet shared specific plans for P-300 but will disclose more details during upcoming oncology conferences.
About P-300
P-300 is an oral, small molecule inhibitor that has the potential to provide clinical benefit for patients with advanced prostate cancer, either alone or in combination with other treatments. P-300 works by inhibiting CREBBP/EP300 (also known as CBP/p300), which are proteins that activate genes that promote cancer cell growth and proliferation. Inhibiting these proteins impacts the expression of key cancer drivers, including the androgen receptor (AR) and its variants, making P-300 relevant not only to advanced prostate cancer, but also to other cancer indications as well, either alone or in combination with other treatments.